Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

Shanghai Stock Exchange 688621.SS

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.41

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Debt to Equity Ratio is 0.41 for the year ending December 31, 2023, a 42.12% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.29, a 5.87% change year over year.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.27, a 118.31% change year over year.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.12, a -8.62% change year over year.
Beijing Sun-Novo Pharmaceutical Research Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.14, a 109.87% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shanghai Stock Exchange: 688621.SS

Beijing Sun-Novo Pharmaceutical Research Co., Ltd.

CEO	Mr. Yujing Liu
IPO Date	June 21, 2021
Location	China
Headquarters	Building 7
Employees	1,370
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Cosmetics Drugstores & Retail Pharmacies Vaccines

Description

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of chemical drugs and peptide drugs in China. The company offers small molecule chemical generic drugs; peptide products; and drugs for indications, such as impetigo, acne, renal anemia, chronic kidney disease dialysis patient hyper parathyroid hormone, analgesia, and other symptoms. It also provides packaging material compatibility test, impurity research, extract research, migration research, safety evaluation, and other research services; consistency evaluation services; clinical research services; registration consulting and agency services; and range of pharmacokinetics-pharmacodynamics and GLP bioanalysis services, including pharmacokinetic bioanalysis, immunogenic biology analysis, pharmacodynamics, and biomarker bioanalysis services. The company was founded in 2009 and is based in Beijing, China.

Key trends

Past 5 years